Xeris Biopharma Holdings Inc
2B30
Company Profile
Business description
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Contact
1375 West Fulton Street
Suite 1300
ChicagoIL60607
USAT: +1 844 445-5704
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
394
Stocks News & Analysis
stocks
What did Morningstar subscribers buy and sell during February?
How the most traded shares stack up against our analysts views.
stocks
Paying more for new customers is a troubling sign for ASX share
Shares fall close to 18% after reporting higher marketing expenses.
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.90 | 0.10 | 0.00% |
| CAC 40 | 8,123.15 | 44.58 | -0.55% |
| DAX 40 | 24,097.30 | 108.06 | -0.45% |
| Dow JONES (US) | 48,739.41 | 238.14 | 0.49% |
| FTSE 100 | 10,549.29 | 18.36 | -0.17% |
| HKSE | 25,321.34 | 71.86 | 0.28% |
| NASDAQ | 22,807.48 | 290.79 | 1.29% |
| Nikkei 225 | 55,278.06 | 1,032.52 | 1.90% |
| NZX 50 Index | 13,617.89 | 86.77 | 0.64% |
| S&P 500 | 6,869.50 | 52.87 | 0.78% |
| S&P/ASX 200 | 8,940.30 | 3.10 | -0.03% |
| SSE Composite Index | 4,108.57 | 26.09 | 0.64% |